1 / 21

Allogenic Stem Cell Transplantation for MDS

Allogenic Stem Cell Transplantation for MDS. 林建廷 April 28, 2008. Indicated?. IPSS for MDS (FAB classification) Greenberg P et al . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088. (Erratum in Blood 1998; 91: 1100)

kanan
Download Presentation

Allogenic Stem Cell Transplantation for MDS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Allogenic Stem Cell Transplantation for MDS 林建廷 April 28, 2008

  2. Indicated? • IPSS for MDS (FAB classification) • Greenberg P et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088. (Erratum in Blood 1998; 91: 1100) • WPSS for MDS (WHO classification) • Germany. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25: 3503-3510.

  3. Free from

  4. Indicated? • IPSS for MDS (FAB classification) • Greenberg P et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088. (Erratum in Blood 1998; 91: 1100) • WPSS for MDS (WHO classification) • Germany. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25: 3503-3510.

  5. OS Risk of AML Time-dependent WPSS

  6. Both from IPSS and WPSS, the estimated OS is about 2 yrs, and 5-yr survival probability is about 15-25% • Therefore, further treatment other than BSC is indicated. • ATG/CsA • Azacitidine/Decitabine • Allo-SCT

  7. Will respond to immunosuppression? • NIH. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003; 102: 3025-3027. • ATG + CsA (regardless of blast percentage)

  8. HCT-Comorbidity index(HCT-CI) from Fred Hutchinson CRC • Fred Hutchinson CRC. Hematopoietic cell transplantation-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106: 2912-2919 • Ablative (n=761) vs nonablative (n=294) • Related (58%) vs unrelated (42%) • PB(71%) vs Marrow(29%) • GVHD prophylaxis with CsA/MTX(82%) or CsA/MMF(18%) • GVHD tx with steroid or reinstitution of CsA • Infection prophylaxis with Fluconazole, (Ceftazidime or Ciproxin), (Baktar or Dapsone), Acyclovir if sero(+)

  9. Causes of Non-relapse Mortality(NRM) • N=122 • Pulmonary toxicities (24%) • GVHD (11%) • Infections (45%) • Infection + GVHD (18%) • Infection – GVHD (27%) • Others (20%) • HCT-CI did not take into consideration including age, underlying disease and type of transplantation

  10. 50-point Pretransplantation Assessment of Mortality (PAM) Score • Predict 2-yr Allo-SCT mortality (any cause) • Fred Hutchinson CRC. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med. 2006; 144: 407-414 • n=2802 • Predict survival within 2 yrs

  11. Age Donor type Dz risk Conditioning regimen FEV1 DLCO Cre GPT

  12. Predict AML/MDS allo-SCT Risk/Benefit • Fred Hutchinson CRC. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007; 25: 4246-4254

More Related